新規遅延性ナトリウムチャネル電流阻害薬NCC-3902の抗不整脈作用

DOI Web Site 被引用文献2件

書誌事項

タイトル別名
  • NCC-3902, a novel late sodium current blocker, exhibits potent antiarrhythmic effect in isolated guinea pig pulmonary vein and canine rapid atrial pacing model

抄録

<p>Atrial fibrillation (AF) is caused by an interaction between an &quot;initiating trigger&quot; such as ectopic activity in the pulmonary vein (PV) and a &quot;vulnerable status&quot; such as an atrial effective refractory period (ERP) shortening. Controlling both causal factors is an ideal therapeutic strategy for AF, but it is difficult to be achieved by existing drugs. We hypothesized that the blockade of persistent component of the sodium current (late INa; INaL) could be an innovative approach for AF treatment. Using NCC-3902; a selective INaL blocker, we examined whether inhibition of INaL has an effect on ectopic activity, atrial ERP, and AF induction.</p><p>NCC-3902 blocked INaL, but had no effect on other major cardiac ion channel currents stably expressed in cell lines. In isolated guinea pig PV, NCC-3902 decreased the automatic firing frequency of the myocardium. In canine rapid atrial pacing models, NCC-3902 prolonged the ERP and intra atrial conduction time in a dose-dependent manner. In addition, NCC-3902 suppressed AF induction without proarrhythmic potentials. Our results suggest that the blockade of INaL could achieve an ideal AF management with controlling both an &quot;initiating trigger&quot; and a &quot;vulnerable status&quot; without proarrhythmic potentials. A novel INaL blocker, NCC-3902, could bring more effective and safer approach for AF treatment.</p>

収録刊行物

被引用文献 (2)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ